HIV vaccine passes first safety test in infants
NCT ID NCT04607408
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental HIV vaccine in 38 healthy infants born to HIV-positive mothers. The vaccine was designed to teach the immune system to recognize HIV. The main goal was to see if it was safe and whether it triggered an immune response. The study is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HIV-1 CH505 transmitted/founder gp120 protein vaccine with GLA-SE adjuvant
- What this could lead to
- If it works, this could point toward a safe vaccine to protect infants from HIV infection.
- What could go wrong
- This is a very early phase 1 trial with only 38 infants, so it cannot prove the vaccine prevents HIV. It only tested safety and basic immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Perinatal HIV Research Unit (PHRU), Soweto CRS
Johannesburg, Gauteng, 1862, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?